Feeds:
Posts
Comments

Archive for the ‘Hormone-refactory’ Category

URO TODAY:  Stopping the enzyme process that allows a prostate tumour to produce androgens could be the key in halting a tumour’s growth, researchers in Texas say. READ MORE>

Prostate cancer advances when tumors become resistant to hormone therapy, which is the standard treatment for patients, and begin producing their own androgens.

Read Full Post »

US NATIONAL CANCER INSTITUTE: Scientists are making progress towards finding a life-extending treatment option for men with metastatic castration-resistant prostate cancer. READ MORE>

Read Full Post »

URO TODAY:  Abiraterone acetate is a promising treatment for advanced prostate cancer patients and is being tested in a Phase III trial for men with progressive castration-resistant prostate cancer who have  not had chemotherapy.

A Phase III trial for patients following prior chemotherapy has been completed and is awaiting analysis. READ MORE>

Read Full Post »

URO TODAY: Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness, and two new drugs are showing promise in preventing that happen. READ MORE>

Notably, promising activity has been shown in early phase trials by MDV3100, a new anti-androgen designed for activity in prostate cancer model systems with over-expressed androgen receptor, and by abiraterone acetate, a CYP17A inhibitor that blocks steroid biosynthesis in the adrenal gland and possibly within the tumour. Both agents are undergoing phase three testing.

Read Full Post »

URO TODAY: A combination of docetaxel/zoledronic/prednisone in chemotherapy for hormone refractory prostate cancer patients is safe and effective, say Indian researchers. For patients with a Gleason score less than 7, PSA declined more than 50% and those who received more than four cycles had significantly better survival. READ MORE>

Read Full Post »

URO TODAY: Depression and cognitive loss are common in men on hormone therapy for prostate cancer and early treatment with anti-depressants is recommended, according to a paper on HT side effects presented at a conference in Turkey. READ MORE>

Read Full Post »

URO TODAY: Once, chemotherapy (then death) were the only options left for prostate cancer patients on whom hormone therapy stopped working: now new drugs give hope of extended life. READ MORE>

Read Full Post »

Older Posts »

Follow

Get every new post delivered to your Inbox.